Dr. Singh Discusses the Next Steps for Immunotherapy in GISTs

Arun S. Singh, MD
Published: Tuesday, Apr 10, 2018



Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the next steps following a trial investigating single-agent and combination immunotherapy for patients with gastrointestinal stromal tumors (GIST).

This phase II trial examined the role of single-agent nivolumab (Opdivo) versus nivolumab plus ipilimumab (Yervoy). Currently, 14 patients have been enrolled on the study and 8 remain on treatment. Stable disease was the best response in 3 of 7 patients treated with nivolumab monotherapy and 1 partial response and 2 patients with stable disease were reported for the nivolumab/ipilimumab arm.

One-third of patients have received benefit, not just in terms of disease shrinkage but a prolonged disease control, which is important for the group, says Singh. The real question is why those patients are receiving benefit. In a separate ongoing study, physicians are looking at predictive biomarkers to try to identify who is responding, why they are responding, or reasons why patients do not respond to immunotherapy.
 


Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the next steps following a trial investigating single-agent and combination immunotherapy for patients with gastrointestinal stromal tumors (GIST).

This phase II trial examined the role of single-agent nivolumab (Opdivo) versus nivolumab plus ipilimumab (Yervoy). Currently, 14 patients have been enrolled on the study and 8 remain on treatment. Stable disease was the best response in 3 of 7 patients treated with nivolumab monotherapy and 1 partial response and 2 patients with stable disease were reported for the nivolumab/ipilimumab arm.

One-third of patients have received benefit, not just in terms of disease shrinkage but a prolonged disease control, which is important for the group, says Singh. The real question is why those patients are receiving benefit. In a separate ongoing study, physicians are looking at predictive biomarkers to try to identify who is responding, why they are responding, or reasons why patients do not respond to immunotherapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x